IP Library Granted Patent US 8,440,455
Granted Patent B2
US 8,440,455 · App. 12/675,011 · Granted May 14, 2013

Plasmic production and expression of recombinant proteins in cells grown without antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,455
App. No.
12/675,011
Granted
May 14, 2013
Kind
B2
Abstract

The invention relates to a mutated cell such as a bacteria or yeast in which the thyA gene coding thymidylate synthase includes a nonsense codon, preferably the amber codon, said nonsense codon replacing a codon coding an amino acid and inducing the interruption of thyA gene translation and the auxotrophy of the cell for the thymidine. Advantageously, the endA gene coding the endonuclease 1 and/or the recA gene coding the recombinase is inactivated in said mutated cell. The invention also relates to an expression plasmid including a transgene and a sequence of a suppressing ARM structural gene containing an anticodon that can be paired with the nonsense codon of the thyA gene and is specific of an amino acid capable of restoring the translation of the mutated thyA gene and thereby obtaining a protein of the wild or mutated type having a thymidylate synthase activity. The invention also relates to a method for the multiplication of the expression plasmid.

Claims (12)

1. An expression plasmid comprising:

the sequence set forth in SEQ ID NO: 21, and

an expression cassette comprising a nucleotide sequence coding for a recombinant protein of interest.

2. The expression plasmid of claim 1 , wherein the recombinant protein of interest is selected from the group consisting of erythropoietin, dystrophin, insulin, anti-TNFalpha, cytokines, coagulation factors, protective antigens and prostate specific membrane antigen (PSMA).

3. A pharmaceutical composition comprising the expression plasmid of claim 2 .

4. The expression plasmid of claim 2 , wherein the coagulation factor is human factor IX.

5. The expression plasmid of claim 2 , wherein the protective antigens are selected from the group consisting of Bacillus anthracis and Mycobacterium tuberculosis .

6. A method for producing an expression plasmid as defined in claim 1 , said method comprising:

transforming a mutated E.coli cell with the expression plasmid as defined in claim 1 ; wherein the thyA gene coding for thymidylate synthase of said mutated E.coli cell contains a nonsense amber codon UAG, said nonsense codon replacing a codon coding for histidine in position 147 of the thyA gene and leading to interruption of the translation of the thyA gene and auxotrophy of said mutated E.coli cell for thymidine,

growing said transformed mutated E.coli cell, and

extracting the plasmid defined in claim 1 from the cell culture,

said mutated E.coli cell being grown in a medium free of thymidine in order to allow selection of the cell transformed by said plasmid defined in claim 1 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jan 11, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 062387/0489 →
CHANGE OF NAME Recorded Jun 20, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060390/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2011
From: SHERMAN, DANIEL; MARIE, CORINNE
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 026278/0044 →